Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.

Ibrahim R, Han W, Wang W, Kau E, Said N, Forst B, Pham HN, Abdelnabi M, Salih M, Ali NB, Farina J, Lester SJ, Lee K, Ayoub C, Arsanjani R

Journal of the American Heart Association11 Dec 2025Cited by 1 (Europe PMC)

PMID41378487PMCIDPMC12826936DOI10.1161/jaha.125.044577PepBankPUB-41378487

Read at source PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, pooled GLP-1 RA therapy (semaglutide or tirzepatide) was associated with fewer acute HF events than bariatric surgery.
In plain wordsIn adults with heart failure and obesity, GLP-1 drugs as a group were linked to fewer heart failure events than weight-loss surgery.
Peptide
Semaglutide
Outcome
DecreaseAcute heart failure events
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.78 ratio
acute HF events
Source sentences
Summary
GLP-1 RA therapy was associated with lower incidence of acute HF events (38.9% versus 44.6%; HR, 0.78 [95% CI, 0.72-0.85]), all-cause death (11.1% versus 14.8%; HR, 0.71 [95% CI, 0.61-0.82]), and all-cause hospitalizations (66.4% versus 77.3%; HR, 0.62 [95% CI, 0.58-0.66]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4137848701
02HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, pooled GLP-1 RA therapy (semaglutide or tirzepatide) was associated with fewer acute HF events than bariatric surgery.
In plain wordsIn adults with heart failure and obesity, GLP-1 drugs as a group were linked to fewer heart failure events than weight-loss surgery.
Peptide
Tirzepatide
Outcome
DecreaseAcute heart failure events
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.78 ratio
acute HF events
Source sentences
Summary
GLP-1 RA therapy was associated with lower incidence of acute HF events (38.9% versus 44.6%; HR, 0.78 [95% CI, 0.72-0.85]), all-cause death (11.1% versus 14.8%; HR, 0.71 [95% CI, 0.61-0.82]), and all-cause hospitalizations (66.4% versus 77.3%; HR, 0.62 [95% CI, 0.58-0.66]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4137848702
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, pooled GLP-1 RA therapy (semaglutide or tirzepatide) was associated with fewer all-cause hospitalizations than bariatric surgery.
In plain wordsIn adults with heart failure and obesity, GLP-1 drugs as a group were linked to fewer hospital stays than weight-loss surgery.
Peptide
Semaglutide
Outcome
DecreaseAll-cause hospitalizations
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.62 ratio
all-cause hospitalizations
Source sentences
Summary
GLP-1 RA therapy was associated with lower incidence of acute HF events (38.9% versus 44.6%; HR, 0.78 [95% CI, 0.72-0.85]), all-cause death (11.1% versus 14.8%; HR, 0.71 [95% CI, 0.61-0.82]), and all-cause hospitalizations (66.4% versus 77.3%; HR, 0.62 [95% CI, 0.58-0.66]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4137848703
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, pooled GLP-1 RA therapy (semaglutide or tirzepatide) was associated with fewer all-cause hospitalizations than bariatric surgery.
In plain wordsIn adults with heart failure and obesity, GLP-1 drugs as a group were linked to fewer hospital stays than weight-loss surgery.
Peptide
Tirzepatide
Outcome
DecreaseAll-cause hospitalizations
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.62 ratio
all-cause hospitalizations
Source sentences
Summary
GLP-1 RA therapy was associated with lower incidence of acute HF events (38.9% versus 44.6%; HR, 0.78 [95% CI, 0.72-0.85]), all-cause death (11.1% versus 14.8%; HR, 0.71 [95% CI, 0.61-0.82]), and all-cause hospitalizations (66.4% versus 77.3%; HR, 0.62 [95% CI, 0.58-0.66]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4137848704
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, pooled GLP-1 RA therapy (semaglutide or tirzepatide) was associated with lower all-cause death than bariatric surgery.
In plain wordsIn adults with heart failure and obesity, GLP-1 drugs as a group were linked to fewer deaths than weight-loss surgery.
Peptide
Semaglutide
Outcome
DecreaseAll-cause death
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Measurements
HR
0.71 ratio
all-cause death
Source sentences
Summary
GLP-1 RA therapy was associated with lower incidence of acute HF events (38.9% versus 44.6%; HR, 0.78 [95% CI, 0.72-0.85]), all-cause death (11.1% versus 14.8%; HR, 0.71 [95% CI, 0.61-0.82]), and all-cause hospitalizations (66.4% versus 77.3%; HR, 0.62 [95% CI, 0.58-0.66]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4137848705
06HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, pooled GLP-1 RA therapy (semaglutide or tirzepatide) was associated with lower all-cause death than bariatric surgery.
In plain wordsIn adults with heart failure and obesity, GLP-1 drugs as a group were linked to fewer deaths than weight-loss surgery.
Peptide
Tirzepatide
Outcome
DecreaseAll-cause death
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Measurements
HR
0.71 ratio
all-cause death
Source sentences
Summary
GLP-1 RA therapy was associated with lower incidence of acute HF events (38.9% versus 44.6%; HR, 0.78 [95% CI, 0.72-0.85]), all-cause death (11.1% versus 14.8%; HR, 0.71 [95% CI, 0.61-0.82]), and all-cause hospitalizations (66.4% versus 77.3%; HR, 0.62 [95% CI, 0.58-0.66]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4137848706
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, myocardial infarction rates were similar with pooled GLP-1 RA therapy (semaglutide or tirzepatide) and bariatric surgery.
In plain wordsIn adults with heart failure and obesity, heart attack rates were similar with GLP-1 drugs as a group and with weight-loss surgery.
Peptide
Semaglutide
Outcome
No significant changeMyocardial infarction
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.99 ratio
myocardial infarction
Source sentences
Summary
Rates of myocardial infarction (13.8% versus 13.4%; HR 0.99 [0.86-1.14]) and stroke (9.7% versus 10.7%; HR, 0.87 [0.74-1.02]) were similar between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4137848707
08HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, myocardial infarction rates were similar with pooled GLP-1 RA therapy (semaglutide or tirzepatide) and bariatric surgery.
In plain wordsIn adults with heart failure and obesity, heart attack rates were similar with GLP-1 drugs as a group and with weight-loss surgery.
Peptide
Tirzepatide
Outcome
No significant changeMyocardial infarction
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.99 ratio
myocardial infarction
Source sentences
Summary
Rates of myocardial infarction (13.8% versus 13.4%; HR 0.99 [0.86-1.14]) and stroke (9.7% versus 10.7%; HR, 0.87 [0.74-1.02]) were similar between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4137848708
09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, stroke rates were similar with pooled GLP-1 RA therapy (semaglutide or tirzepatide) and bariatric surgery.
In plain wordsIn adults with heart failure and obesity, stroke rates were similar with GLP-1 drugs as a group and with weight-loss surgery.
Peptide
Semaglutide
Outcome
No significant changeStroke
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.87 ratio
stroke
Source sentences
Summary
Rates of myocardial infarction (13.8% versus 13.4%; HR 0.99 [0.86-1.14]) and stroke (9.7% versus 10.7%; HR, 0.87 [0.74-1.02]) were similar between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4137848709
10HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, stroke rates were similar with pooled GLP-1 RA therapy (semaglutide or tirzepatide) and bariatric surgery.
In plain wordsIn adults with heart failure and obesity, stroke rates were similar with GLP-1 drugs as a group and with weight-loss surgery.
Peptide
Tirzepatide
Outcome
No significant changeStroke
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.87 ratio
stroke
Source sentences
Summary
Rates of myocardial infarction (13.8% versus 13.4%; HR 0.99 [0.86-1.14]) and stroke (9.7% versus 10.7%; HR, 0.87 [0.74-1.02]) were similar between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4137848710
11HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, follow-up body mass index did not differ between pooled GLP-1 RA therapy (semaglutide or tirzepatide) and bariatric surgery.
In plain wordsIn adults with heart failure and obesity, body mass index at follow-up was similar after GLP-1 drugs as a group and after weight-loss surgery.
Peptide
Semaglutide
Outcome
No significant changeFollow-up body mass index
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Mean body mass index at follow-up was 38.0 in the GLP-1 RA cohort versus 37.7 after bariatric surgery (P=0.34).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4137848711
12HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, follow-up body mass index did not differ between pooled GLP-1 RA therapy (semaglutide or tirzepatide) and bariatric surgery.
In plain wordsIn adults with heart failure and obesity, body mass index at follow-up was similar after GLP-1 drugs as a group and after weight-loss surgery.
Peptide
Tirzepatide
Outcome
No significant changeFollow-up body mass index
Study
n = 2,747
Comparator
Bariatric surgery
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Mean body mass index at follow-up was 38.0 in the GLP-1 RA cohort versus 37.7 after bariatric surgery (P=0.34).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4137848712
13HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, follow-up hemoglobin A1c was higher with pooled GLP-1 RA therapy (semaglutide or tirzepatide) than after bariatric surgery.
In plain wordsIn adults with heart failure and obesity, blood sugar marker HbA1c was higher with GLP-1 drugs as a group than after weight-loss surgery.
Peptide
Semaglutide
Outcome
IncreaseFollow-up hemoglobin A1c
Study
n = 2,747
Comparator
Bariatric surgery
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Hemoglobin A_1c at follow-up was higher in the GLP-1 RA group (7.4 versus 6.8; P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4137848713
14HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults with HFpEF and obesity, follow-up hemoglobin A1c was higher with pooled GLP-1 RA therapy (semaglutide or tirzepatide) than after bariatric surgery.
In plain wordsIn adults with heart failure and obesity, blood sugar marker HbA1c was higher with GLP-1 drugs as a group than after weight-loss surgery.
Peptide
Tirzepatide
Outcome
IncreaseFollow-up hemoglobin A1c
Study
n = 2,747
Comparator
Bariatric surgery
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Hemoglobin A_1c at follow-up was higher in the GLP-1 RA group (7.4 versus 6.8; P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the TriNetX research network, we conducted a retrospective cohort study of adults (aged ≥18 years) with HF with preserved ejection fraction and obesity (body mass index >30 kg/m²) from 2017 to 2022.
Summary · context
Patients were categorized into 2 cohorts: those receiving GLP-1 RAs (semaglutide or tirzepatide) and those who underwent bariatric surgery.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4137848714

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.